
SKIPPirr: Evaluating Prophylactic Strategies to Reduce the Incidence of Infusion-related Reactions (IRRs) With Amivantamab


Rationale

- igodol 2 In CHRYSALIS, a phase 1 study, intravenous (IV) amivantamab has an IRR incidence of ~67% at first infusion^{1,a}
- 📀 Standard mitigation approaches in clinical trials include a split first dose of amivantamab over 2 days in the first cycle and premedication with oral or IV antihistamines, oral or IV antipyretics, and IV glucocorticoids1,2




ECOG PS 0–1

One cohort tested in SKIPPirr reached the expansion stage: oral dexamethasone 8 mg cohort³



In SKIPPirr, the Week 1, Day 1 IV dexamethasone dose is 10 mg. In the amivantamab Prescribing Information, the Week 1, Day 1 IV dexamethasone dose is 20 mg.^{2,3}



fStandard IRR management included premedication with antihistamines, antipyretics, and glucocorticoids 8 By C1D15 and onward, the median duration of amivantamab infusion was approximately 2.3 hours for all cohorts

Johnson&Johnson